Navigation Links
Delpor Selected by the NIH to Exhibit its Technology at the 2017 BIO International Convention
Date:5/31/2017

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced that it has been selected by the National Institutes of Health (NIH) to exhibit and showcase its technology at the upcoming International Convention of the Biotechnology Innovation Organization (BIO). The Convention will take place in San Diego, CA on June 19-22, 2017. Delpor will be exhibiting at BIO’s “Innovation Zone” along with other innovative companies.

“We are honored to have been selected as one of the companies to exhibit at BIO’s Innovation Zone, and we are looking forward to having fruitful discussions with potential partners,” said Tassos Nicolaou, President and CEO of Delpor.

During the conference, Delpor expects to focus on its lead program, DLP-114 (6-month risperidone formulation for schizophrenia maintenance treatment) and on its two key implantable drug delivery technologies (PROZOR™ and NANOPOR™).

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic. Delpor’s device can deliver small & large molecules over several months while maintaining zero-order release pharmacokinetics. The company’s lead products include 3-6 month formulations of Risperidone and Exenatide. Additional information about the company can be found at http://www.delpor.com.

About DLP-114
Delpor’s DLP-114 is a small titanium reservoir designed for subcutaneous implantation and loaded with a proprietary formulation of risperidone. The product is designed to provide a constant therapeutic dose of risperidone each day for a total period of 6 months. Additional features are expected to include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Read the full story at http://www.prweb.com/releases/DelporToExhibitat2017Bio/InnovationZone/prweb14380665.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the Treatment of Schizophrenia
2. Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
3. Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
4. SimpleTrials Selected as a Top 10 eClinical Trial Management Solution Provider by Pharma Tech Outlook
5. NewTechBio Selected to Provide Aquatic Remediation Solution to Algae Infested Savannah River Site Experiencing High PH and Phosphorus
6. Inflamax Research selected to join Ontario Premier Kathleen Wynne’s trade mission to Israel
7. Proove CEO and Founder Brian Meshkin Selected as a Finalist for the ACG 21st Annual Awards
8. Pioneering biomedical company selected for Shinzo Abe's “Bridge of Innovation” Initiative
9. Nanotechnology expert selected to lead OHSUs large-scale early cancer detection initiative
10. Apervita Selected by GE Healthcare to Help Expand its Advanced Analytics Footprint
11. AlgaEnergy Selected to Present at CleanEquity Monaco 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/9/2018)... WALTHAM, MAss. (PRWEB) , ... August 09, 2018 ... ... diverse group of architectural, engineering, and construction (AEC) experts with building owners and ... New England. The fourth-annual Create + Construct symposium comes to Boston for the ...
(Date:7/31/2018)... ... July 31, 2018 , ... ... molecular quality controls to its expanding CE/IVD product inventory. , “We are pleased ... CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully support and provide our ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an ... to combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers ... data was reported:, Over 70% decrease in Interleukin ...
(Date:7/24/2018)... ... July 23, 2018 , ... Mark Stutheit, an evidence-based ... increase immunity and improve anti-inflammatory, and immune function responses. , Biomarkers for systemic ... research were significantly reduced. Results are as follows:, , ...
Breaking Biology Technology:
(Date:8/14/2018)... ... August 13, 2018 , ... ... and explore opportunities with multiple health systems at once. However, healthcare professionals often ... offer another, more efficient option for healthcare providers who wish to explore opportunities ...
(Date:8/14/2018)... , ... August 14, 2018 , ... ... compliance and commercialization, is announcing the keynote for their NAVIGATE2018 conference. ... announced as keynote speaker for NAVIGATE2018 , Cognition’s annual user conference. An ...
(Date:8/7/2018)... ... August 06, 2018 , ... Nurse ... remained generally satisfied with their healthcare careers in the past year, according to ... provides healthcare employers and jobseekers with a wide variety of career- and employment-related ...
Breaking Biology News(10 mins):